Home › Trials › NCT06836232

Testing VTX2735 for treating recurrent pericarditis

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis

Phase 2 Interventional Zomagen Biosciences Ltd. · NCT06836232

This study is testing a new drug called VTX2735 to see if it can help people with recurrent pericarditis feel better and reduce their symptoms.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment50 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorZomagen Biosciences Ltd. Industry-sponsored
Locations17 sites (Tucson, Arizona and 16 other locations)
Trial IDNCT06836232 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of VTX2735 in patients diagnosed with recurrent pericarditis. Approximately 30 participants will undergo a 30-day screening period followed by a 6-week open-label treatment phase where they will receive the active drug. If they meet specific criteria, they may continue treatment for an additional 7 weeks, followed by a 14-day follow-up period. The study aims to assess the impact of VTX2735 on symptoms and inflammation associated with recurrent pericarditis.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 75 with a history of recurrent pericarditis and ongoing symptoms.

Not a fit: Patients with pericarditis caused by specific conditions such as tuberculosis or autoimmune diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate symptoms and improve the quality of life for patients suffering from recurrent pericarditis.

How similar studies have performed: While this approach is novel, previous studies on NLRP3 inhibitors have shown promise in related inflammatory conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants are male or female ≥ 18 years up to ≤ 75 years of age.
* Capable of giving signed informed consent and able to comply with the protocol
* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
* Pericarditis pain score ≥ 4 based on the 11-point NRS.
* Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)

Exclusion Criteria:

* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
* History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.

Where this trial is running

Tucson, Arizona and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Recurrent PericarditisVentyxZomagenVTX2735NLRP3 InhibitorNLRP3Inflammasome
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.